CNSP News and Press, CNS Pharmaceuticals Inc. From 05/11/21

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO John Climaco will present at the Q2 Virtual Investor Summit at 12...

CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit - Live video webcast with CEO, John Climaco, on Tuesday, May 18, 2021 at 12:30 PM ET PR Newswire HOUSTON , May 11, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or...

During Phase 1 trials, Berubicin showed 44% of patients experienced a clinical benefit of stable disease or better, one being cancer-free after 14 years, and two patients reporting significant tumor reduction (up to 80%) Additional research to be conducted by sublicensee partner WPD Pha...

A mathematical model developed by scientists from Sweden’s Chalmers University of Technology has been designed to help researchers create tailored diets and new probiotics to prevent illnesses. The lead author of the study, Prof. Jens Nielsen, explained that intestinal bacteria pl...

A group of scientists from Stanford University in collaboration with Genentech, a biotechnology corporation, has created a system based on AI that can be used to safely add participants to clinical trials that they may have previously been barred from. The group’s findings were repo...

CNS Pharmaceuticals (NASDAQ: CNSP) is working to determine the efficacy of its lead drug candidate, Berubicin, for the treatment of glioblastoma multiforme (“GBM”), an aggressive type of brain cancer for which there is currently no cure. Promising results were demonstrated wh...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently ...

A new study conducted by researchers from the University of Minnesota Medical School and their colleagues has found three phenotypes of the novel coronavirus, which demonstrate distinct characteristics as well as different clinical outcomes, complications and comorbidities in patient popul...

4 Penny Stocks to Watch as Stimulus Checks Roll In Markets were mixed at the open this morning, but it’s been a more bullish trend for penny stocks. In this case, let’s take a look at the Russell 2000 Small-Cap ETF ( NYSE: IWM ). As you’ll see, in tandem with ot...

The following slide deck was published by CNS Pharmaceuticals, Inc. in conjunction with this event. For further details see: CNS Pharmaceutical (CNSP) Investor Presentation - Slideshow